14,287 Shares in Gilead Sciences, Inc. $GILD Purchased by Grant Private Wealth Management Inc

Key Points

• Grant Private Wealth Management Inc. has acquired a new stake in Gilead Sciences, Inc. valued at approximately $1.58 million, purchasing 14,287 shares during the second quarter.
• Insider trading activities show significant sales, with CEO Daniel O'Day selling 10,000 shares and another insider, Johanna Mercier, selling 28,000 shares, resulting in a decrease in their ownership.
• Analysts maintain a positive outlook for Gilead Sciences, with recent upgrades leading to a consensus rating of "Moderate Buy" and a price target of $117.17.

Grant Private Wealth Management Inc purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 14,287 shares of the biopharmaceutical company's stock, valued at approximately $1,584,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Farther Finance Advisors LLC boosted its holdings in shares of Gilead Sciences by 11.3% in the second quarter. Farther Finance Advisors LLC now owns 41,710 shares of the biopharmaceutical company's stock valued at $4,624,000 after buying an additional 4,223 shares during the period. Silver Oak Securities Incorporated acquired a new stake in Gilead Sciences in the second quarter valued at $415,000. CX Institutional lifted its stake in Gilead Sciences by 2.7% in the second quarter. CX Institutional now owns 70,493 shares of the biopharmaceutical company's stock valued at $7,816,000 after acquiring an additional 1,846 shares during the last quarter. Wright Investors Service Inc. lifted its stake in Gilead Sciences by 0.6% in the second quarter. Wright Investors Service Inc. now owns 50,947 shares of the biopharmaceutical company's stock valued at $5,648,000 after acquiring an additional 282 shares during the last quarter. Finally, My Legacy Advisors LLC bought a new position in shares of Gilead Sciences in the second quarter valued at about $360,000. Institutional investors and hedge funds own 83.67% of the company's stock.

Gilead Sciences Stock Up 1.9%

NASDAQ GILD traded up $2.13 on Tuesday, hitting $114.62. 3,483,414 shares of the company were exchanged, compared to its average volume of 8,064,619. The company has a market cap of $142.23 billion, a PE ratio of 22.84, a PEG ratio of 0.77 and a beta of 0.36. Gilead Sciences, Inc. has a 12 month low of $81.83 and a 12 month high of $121.83. The stock has a fifty day moving average of $114.11 and a 200-day moving average of $109.95. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.96 by $0.05. The business had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. Gilead Sciences's revenue was up 1.4% on a year-over-year basis. During the same period in the prior year, the firm earned $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be paid a dividend of $0.79 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.16 annualized dividend and a yield of 2.8%. Gilead Sciences's dividend payout ratio is currently 62.95%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on GILD shares. Daiwa America raised shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, August 19th. Dbs Bank raised shares of Gilead Sciences to a "moderate buy" rating in a research report on Friday, September 5th. Needham & Company LLC raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price target on the stock in a research report on Friday, July 25th. UBS Group raised their price target on shares of Gilead Sciences from $108.00 to $112.00 and gave the stock a "neutral" rating in a research report on Friday, August 8th. Finally, Rothschild & Co Redburn raised their price target on shares of Gilead Sciences from $136.00 to $143.00 and gave the stock a "buy" rating in a research report on Friday, September 12th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $117.17.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O'day sold 10,000 shares of the business's stock in a transaction on Thursday, August 28th. The shares were sold at an average price of $113.63, for a total transaction of $1,136,300.00. Following the completion of the sale, the chief executive officer owned 595,725 shares in the company, valued at approximately $67,692,231.75. The trade was a 1.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction on Monday, September 15th. The shares were sold at an average price of $113.57, for a total transaction of $283,925.00. Following the sale, the chief financial officer owned 159,555 shares of the company's stock, valued at $18,120,661.35. This trade represents a 1.54% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 82,000 shares of company stock worth $9,390,030. 0.27% of the stock is owned by corporate insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.